Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage

Antimicrobial Agents and Chemotherapy
Steven HagensUdo Bläsi

Abstract

Bacteriophage therapy of bacterial infections has received renewed attention owing to the increasing prevalence of antibiotic-resistant pathogens. A side effect of many antibiotics as well as of phage therapy with lytic phage is the release of cell wall components, e.g., endotoxins of gram-negative bacteria, which mediate the general pathological aspects of septicemia. Here we explored an alternative strategy by using genetically engineered nonreplicating, nonlytic phage to combat an experimental Pseudomonas aeruginosa infection. An export protein gene of the P. aeruginosa filamentous phage Pf3 was replaced with a restriction endonuclease gene. This rendered the Pf3 variant (Pf3R) nonreplicative and concomitantly prevented the release of the therapeutic agent from the target cell. The Pf3R phage efficiently killed a wild-type host in vitro, while endotoxin release was kept to a minimum. Treatment of P. aeruginosa infections of mice with Pf3R or with a replicating lytic phage resulted in comparable survival rates upon challenge with a minimal lethal dose of 3. However, the survival rate after phage therapy with Pf3R was significantly higher than that with the lytic phage upon challenge with a minimal lethal dose of 5. This highe...Continue Reading

References

Oct 1, 1992·Journal of Medical Microbiology·J S Soothill
May 1, 1989·Microbial Pathogenesis·A D O'BrienR K Holmes
Dec 1, 1989·Clinical Immunology and Immunopathology·M R ShalabyT Espevik
May 1, 1973·Canadian Journal of Microbiology·D E Bradley
Oct 1, 1974·Journal of General Microbiology·V A Stanisich
Jan 1, 1983·Molecular & General Genetics : MGG·M G MarinusJ A Arraj
Mar 1, 1983·Reviews of Infectious Diseases·G P BodeyL Jadeja
Aug 1, 1995·FEMS Microbiology Reviews·R Young, U Bläsi
Apr 16, 1996·Proceedings of the National Academy of Sciences of the United States of America·C R MerrilS Adhya
Jun 28, 1996·Science·M K Waldor, J J Mekalanos
Jul 1, 1997·Trends in Microbiology·P A Barrow, J S Soothill
Feb 22, 2001·Antimicrobial Agents and Chemotherapy·A SulakvelidzeJ G Morris
Jul 18, 2002·Intensive Care Medicine·P M LepperM Trautmann
Jul 24, 2002·Clinica Chimica Acta; International Journal of Clinical Chemistry·Didier Heumann, Thierry Roger
Mar 5, 2003·The Journal of Experimental Medicine·Akira NakamuraToshihiro Nukiwa
May 31, 2003·Nature Reviews. Drug Discovery·Carl R MerrilSankar L Adhya
Sep 13, 2003·Letters in Applied Microbiology·S Hagens, U Bläsi

❮ Previous
Next ❯

Citations

Mar 4, 2009·Proceedings of the National Academy of Sciences of the United States of America·Timothy K Lu, James J Collins
May 23, 2009·Foodborne Pathogens and Disease·Stephen T Abedon
Apr 20, 2013·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Susan HoeReinhard Vehring
Sep 28, 2006·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Steven HagensUdo Bläsi
Nov 23, 2006·Antimicrobial Agents and Chemotherapy·Ryohei WatanabeKeizo Yamaguchi
Jan 20, 2011·Antimicrobial Agents and Chemotherapy·Chih-Hsin HungNina Tsao
Mar 12, 2008·Antimicrobial Agents and Chemotherapy·Dean Scholl, David W Martin
Apr 15, 2009·Antimicrobial Agents and Chemotherapy·Yun-Jeong HeoYou-Hee Cho
Apr 29, 2008·Applied and Environmental Microbiology·Steven R WilliamsDean Scholl
Oct 27, 2009·Applied and Environmental Microbiology·Samantha K WallPaul D Ebner
Feb 22, 2012·Canadian Journal of Microbiology·Karlene H Lynch, Jonathan J Dennis
Jun 30, 2012·The European Respiratory Journal·Matthew N HurleyAlan R Smyth
Sep 2, 2011·BMC Microbiology·Vivek Daniel PaulJanakiraman Ramachandran
Jan 12, 2013·Current Protein & Peptide Science·Zuzanna Drulis-KawaRob Lavigne
Jul 5, 2013·Acta Biomaterialia·Rebecca FarrSeung-Wuk Lee
Nov 26, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Bettina M Knoll, Eleftherios Mylonakis
Jun 27, 2007·Proceedings of the National Academy of Sciences of the United States of America·Timothy K Lu, James J Collins
Jul 18, 2014·Scientifica·Stephen T Abedon
May 30, 2014·The Journal of Antimicrobial Chemotherapy·Tania Mareike ViertelHans-Peter Horz
Feb 22, 2012·Expert Review of Anti-infective Therapy·Joanne L FothergillChloe E James
Dec 10, 2014·Expert Review of Anti-infective Therapy·Wessam A Sarhan, Hassan M E Azzazy
Sep 24, 2013·Expert Review of Anti-infective Therapy·James Soothill
Dec 22, 2015·International Journal of Medical Microbiology : IJMM·Maitrayee ChatterjeeRaja Biswas
Aug 27, 2011·Current Opinion in Microbiology·Timothy K Lu, Michael S Koeris
Jul 21, 2011·International Journal of Pharmaceutics·Munerah AlfadhelChristopher F van der Walle
Mar 5, 2016·World Journal of Microbiology & Biotechnology·Amir Mohaghegh MotlaghRamesh Goel
Jan 6, 2009·Letters in Applied Microbiology·P GarcíaA Rodríguez
Jan 25, 2011·Microbial Biotechnology·Jens KrollAlexander Steinbüchel
Aug 26, 2011·British Journal of Pharmacology·Geraint B RogersKenneth D Bruce
Nov 23, 2006·Trends in Biotechnology·Nicola K PettyGeorge P C Salmond
Nov 1, 2005·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Shigenobu MatsuzakiShosuke Imai
Feb 26, 2016·Integrative Biology : Quantitative Biosciences From Nano to Macro·Antonia P SagonaAlfonso Jaramillo
Feb 25, 2015·Trends in Microbiology·Franklin L NobregaJoana Azeredo
Jun 22, 2011·Biotechnology Advances·Zahra Moradpour, Abdollah Ghasemian
Jul 6, 2014·Current Opinion in Microbiology·Robert J CitorikTimothy K Lu
Oct 16, 2012·Virology·Marine Henry, Laurent Debarbieux

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Proceedings of the National Academy of Sciences of the United States of America
Carl R MerrilSankar Adhya
Proceedings of the National Academy of Sciences of the United States of America
Timothy K Lu, James J Collins
© 2021 Meta ULC. All rights reserved